drugs to displace BSP from ligandin and Z protein in vitro. The effects of the drugs on the distribution of bilirubin in the liver cell and its subfractions in rats with congenital unconjugated hyperbilirubinaemia was also investigated.
Male Sprague-Dawley rats (body weight 325-450g) or homozygous Gunn rats (body weight 355-495g) were used. Gunn rats are congenitally jaundiced, due to a deficiency ofglucuronyl transferase. Animals were fed ad libitum Spillers' laboratory no. 1 diet.
The following preparations were used: BSP solution, 50 mg/ml (Hynson, Westcott, and Dunning, Inc, USA); rifamycin-SV, 25 mg/ml (Rifocin, Lepetit); and flavaspidic acid-N-methylglucaminate (Dr Esa Aho, Turku, Finland) dissolved in water for injection BP as necessary. In the experiments in vivo, all compounds were injected into the penile vein in a volume of 0.1 ml/100 g body weight.
Bilirubin was estimated in serum by the technique of Michaelsson, Nosslin, and Sjohn (1965) or by the method of Van Roy, Meuwissen, De Meuter, and Heirwegh (1971) , modified by the addition of the anti-oxidant 2,6-di-tert-butyl-p-cresol (Mertens, Van de Vijver, and Heirwegh, 1972 Rifamycin concentrations in rat liver supernatant were measured by a modification of the spectrophotometric assay of Paunescu and Stoinescu (1969) .
THE EFFECT OF THE DRUGS ON THE PLASMA CLEARANCE OF BSP
The initial plasma disappearance rate of BSP was measured as previously described (Reyes, Levi, Gatmaitan, and Arias, 1969) . Blood samples were taken from a sliced tail vein every 30 seconds between two and eight minutes after the intravenous injection of BSP, 6 gmol/100 g body weight. The concentrations of BSP were plotted on semilogarithmic paper against time. The best fit line was drawn for determination of the ti and the initial plasma disappearance rate, K,, calculated (K, = -). The BSP K, was determined after the injection of BSP alone and also in the following groups of animals in which BSP was injected at various times after the injection of saline or test drug: (1) five minutes after saline; (2) 10, 30, and 60 minutes after rifamycin-SV 3.6 ,umol/100 g body weight; (3) at similar times after flavaspidic acid 5 gmol/100 g body weight.
The drugs did not interfere with BSP estimation.
EFFECT OF DRUGS in vitro ON BSP BINDING BY PROTEIN FRACTIONS
Bromsulphthalein bound to the-ligandin and Z protein fractions was measured by triangulation of the area under the respective peaks following Sephadex G-75 gel filtration at 4°C of the 100 000 x g rat liver supernatant . Bromsulphthalein and saline or the test drug were added in vitro. A typical result is shown in figure 1 'Column size 39 x 2-5 cm, flow rate 3-4 ml/tube/9 min OD 280 nm indicates protein, OD 580 nm indicates BSP (after alkalinization). parable columns were used 2.5 x 40 (± 1) cm, flow rate 3.2 (± 0-3) ml/9 minutes. The aliquots of supernatant were equivalent to 1 g of liver and were prepared from pooled liver homogenate from Sprague-Dawley rats. These techniques of separation give reproducible results provided that experimental conditions are kept constant. The SE of the mean value of BSP bound to the protein fractions is less than 3 % for ligandin and less than 7.5 % for Z protein, in any one series of experiments.
STUDIES ON GUNN RATS in vivo
The effect of rifamycin-SV or flavaspidic acid on bilirubin concentration in serum, liver homogenate, and supernatant was studied in Gunn rats. Liver pellet values were calculated as the difference between liver homogenate and supernatant values. The drug doses were the same as those used above. In separate experiments the effect of the drugs on bilirubin bound to X, ligandin, and Z fractions was investigated using Sephadex G-75 gel filtration. In these experiments the columns, which were protected from light, were 2.5 x 90 (± 1) cm flow rate 5 (± 0.5) ml/9 minutes. 45-5 (2.2)1 32-9 (1-6) 12-6 (1.9) Rifamycin-SV Levi et al, 1969; Fleischner and Arias, 1970 The rifamycin antibiotics in clinical use are selectively taken up by the liver and excreted in high concentration in the bile. Serum bilirubin levels often rise following treatment and several mechanisms seem to be involved (Acocella and Billing, 1965; Acocella, Nicolis, and Tenconi, 1965; Cohn, 1969; Lees, Allan, Smith, Tyrrell, and Fallon, 1971; Capelle et al, 1972) . A transient rise in the serum unconjugated bilirubin seems to be particularly common, although this effect usually disappears during the first two weeks of treatment. This rise is apparently caused by impaired hepatic uptake and not by increased red cell destruction or hepatotoxicity (Cohn, 1969) . The rifamycins also depress the fractional clearance of ICG and BSP Paumgartner, Probst, Kraine, and -dn (table III) . These results suggest that rifamycin-SV might be blocking the uptake of bilirubin and BSP at the level of the plasma membrane and preventing them from entering the liver cell. This view is supported by the completely different pattern of displacement of bilirubin which was found when rifamycin-SV was added in vitro to Gunn supernatant and produced selective displacement from Z protein. Although rifamycin antibiotics do not seem to compete with bilirubin for binding to albumin (Cohn, 1969) , the possibility that rifamycin-SV causes a change in the conformation of the albumin-bilirubin complex has not been explored in this study. Such a change could affect the binding of bilirubin to albumin or the dissociation of the complex at the plasma membrane. This does not seem to be a probable mechanism as the reductions in bilirubin in the liver cell and its fractions suggest that efflux of bilirubin from the liver cell is relatively unimpaired. Levi et al (1969) suggested that flavaspidic acid, the main chemical responsible for the unconjugated hyperbilirubinaemia following administration of male fern extract (Nosslin and Morgan, 1965) , may interfere with the uptake of bilirubin by competing for binding to Z protein. The results here strongly suggest that this is the predominant mechanism. In vivo, total liver bilirubin concentrations were reduced by flavaspidic acid and this reduction was largely accounted for by displacement from Z protein, with increased amounts of bilirubin being found in the liver pellet (table Ill) . The displacement in vitro of BSP from Z protein by very low concentrations of flavaspidic acid suggests that competition for binding to this protein is also the main mechanism of the impaired hepatic uptake of BSP found in vivo (table IV) . The possibility of some interaction occurring at the liver cell membrane, as suggested by Cornelius et al (1967) , working with isolated cell membranes, has not been excluded, but is not a necessary hypothesis to explain these findings, and cannot be the main site of interaction. There was no rise in serum bilirubin levels, with respect to controls, after flavaspidic acid, and this had been previously 3* found by Hammaker and Schmid (1967) . However, the total displacement of bilirubin from the liver was less than after rifamycin-SV even though the flavaspidic acid was given at a relatively higher dose. The analysis of the mechanisms involved in hepatic uptake has been hindered by the complexity and rapidity of the processes involved, and by the technical difficulties of differentiating uptake from other variables. In this study, the initial plasma clearance of BSP was used as the measure of BSP uptake by the liver, and alterations in the tissue distribution of bilirubin in Gunn rats as the measure of net bilirubin uptake.
The physiological role of the acceptor proteins, ligandin and Z, has not been fully explored, but there is evidence that they are important in facilitating the selective hepatic uptake of bilirubin and BSP Levi, Gatmaitain, and Arias, 1970) . Studies on plasma clearance, hepatic transport maxima and storage, multicompartmental analyses, and complex flow techniques have all been used to investigate the problem of hepatic uptake, but without elucidating the role of the plasma membrane or the acceptor proteins and without explaining the mechanism of the hepatic uptake defect produced by a number of drugs. In mutant Southdown sheep there is a hepatic uptake defect for various organic anions (Cornelius and Gronwall, 1968) . Preliminary evidence suggests that there is no major quantitative difference in the acceptor proteins in mutant sheep compared with normal sheep and in these mutants there might be a defect at the level of the plasma membrane (Mia, Gronwall, and Cornelius, 1970) . This could provide further evidence of the importance of the membrane as a site for hepatic selectivity. In man, Berk, Blaschke, and Waggoner (1972) found no close correlation between the hepatic uptake defects for bilirubin, BSP, and indocyanine green in patients with Gilberts' syndrome. This could be additional evidence for different sites of hepatic selectivity.
The present study suggests that competitive uptake studies can be used to clarify the mechanisms of hepatic selectivity. The results also help to elucidate the mechanism of the unconjugated hyperbilirubinaemia found following rifamycin antibiotics. It is suggested that competition with bilirubin might be occurring at the level of the plasma membrane. Flavaspidic acid apparently acts at a different site, largely by competing for binding to Z protein. The study also demonstrates the need for experiments both in vivo and in vitro in assessing the importance of the acceptor proteins. 
